Modalis Therapeutics Corporation announced that it has entered into a Memorandum of Understanding (MOU) with GENIXCURE Inc. which develops novel adeno-associated virus (AAV) vectors and therapeutics using a proprietary AI system. Based on this MOU, Modalis will provide MDL-104, generated with its proprietary epigenome editing technology, CRISPR- GNDM (Guide Nucleotide-Directed Modulation), to GENIXCURE who will use MDL-104 with their proprietary CNS tropic AAV capsid, XOB031, to research and develop a novel gene therapy for the treatment of Alzheimer's disease. MDL-104, which uses naturally occurring AAV9 capsid as a drug delivery technology, has demonstrated significant suppression of the expression of intracellular Tau RNA and protein in target tissues and cells within the CNS upon intra-cisterna magna (ICM) administration in mouse disease models.

Through a collaborative relationship under this MOU, Modalis and GENIXCURE will conduct joint research and development with the aim of transducing high levels of MDL-104 to the brain, with limited exposure to non-targeted tissues, and demonstrating long-term efficacy and safety in murine and large animal species, including NHPs, using a minimally invasive intravenous injection (IV) administration method. The combined expertise of both companies will leverage their experience in AAV engineering and epigenetic modulation to develop best-in-class, IV administered therapies for Alzheimer's Disease and other Tauopathies.